FIELD: biotechnology.
SUBSTANCE: invention relates to detecting the presence of cancer stem cell (CSC) in a sample containing cancer cells. Method includes bringing a sample into contact with an agent which binds to a nucleic acid, expressed sequence CCL20 or amino acid sequence CCL20. Further, the presence or absence of binding between the agent and the nucleic acid, expressed by the CCL20 sequence or the CCL20 amino acid sequence, is detected, and detecting the presence of CSC in the sample upon detecting binding between the agent and the nucleic acid expressed by the CCL20 sequence or the CCL20 amino acid sequence.
EFFECT: disclosed are compositions and methods of treating cancer.
5 cl, 28 dwg, 1 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIAGNOSTICS AND TREATMENT OF CANCER ASSOCIATED WITH CANCER STEM CELLS | 2014 |
|
RU2749867C2 |
| USE OF THE ANTI-O-ACETYLATED GANGLIOSIDE GD2 ANTIBODY FOR IMPROVING THE THERAPEUTIC POTENTIAL OF DRUGS | 2017 |
|
RU2771173C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| IL-10/FC FUSION PROTEINS SUITABLE AS IMMUNOTHERAPY ENHANCERS | 2020 |
|
RU2825306C1 |
| ANTI HUMAN INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN (IL1RAP) ANTIBODIES AND USES THEREOF | 2015 |
|
RU2710787C2 |
| METHODS FOR TREATING CANCER, INCLUDING TIGIT-BINDING AGENTS | 2017 |
|
RU2765410C2 |
| ANTI-LAG-3 DOSING REGIMENS AND THEIR USE | 2018 |
|
RU2801208C2 |
| FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
| COMBINED METHODS FOR TREATING WITH PD-L1 ANTAGONISTS | 2016 |
|
RU2766890C2 |
| SPECIFIC ANTIBODIES TO PD-L1 AND METHODS FOR THEIR APPLICATION | 2017 |
|
RU2749109C2 |
